Genzyme CEO Henri Termeer said the French pharmaceutical company Sanofi-Aventis would have to raise its $69-a-share offer if it wants to discuss the sale of the biotechnology company.
WSJ.com: What's News US, Wall Street Journal
Tue, 08/31/2010 - 6:49pm
Genzyme CEO Henri Termeer said the French pharmaceutical company Sanofi-Aventis would have to raise its $69-a-share offer if it wants to discuss the sale of the biotechnology company.